NEO-MEDROL

Clinical safety rating: caution

Comprehensive clinical and safety monograph for NEO-MEDROL (NEO-MEDROL).

How it works

Neo-Medrol is a combination of neomycin (an aminoglycoside antibiotic) and methylprednisolone (a corticosteroid). Neomycin inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, while methylprednisolone suppresses inflammation by binding to glucocorticoid receptors, modulating gene expression, and inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis.

What the body does with it

Metabolism	Methylprednisolone is primarily metabolized in the liver via CYP3A4. Neomycin is minimally absorbed through intact skin; systemic absorption is negligible.
Excretion	Renal (primarily as inactive metabolites); <5% unchanged. Biliary/fecal excretion minimal.
Half-life	Plasma terminal half-life: 2-4 hours (methylprednisolone); clinical effect half-life ~18-36 hours due to receptor occupancy.
Protein binding	~78% bound to corticosteroid-binding globulin (CBG) and albumin.
Volume of Distribution	Approximately 0.8-1.2 L/kg, indicating extensive tissue distribution.
Bioavailability	Oral: 70-90%; IM: 100% (systemic); Intra-articular or soft-tissue injection: predominantly local with partial systemic absorption (variable).
Onset of Action	IV: rapid, within 30 minutes; IM: 1-2 hours; Oral: 2-4 hours.
Duration of Action	Single dose: 12-36 hours depending on dose and route; prolonged suppression of HPA axis can persist for weeks with chronic use.

Classification & Brands

Dosing & administration

Initial dose: 4-48 mg orally per day, divided into 1-4 doses, depending on severity. Intravenous or intramuscular: 10-500 mg/day as methylprednisolone sodium succinate, given as single or divided doses. Intra-articular or soft tissue injection: 4-80 mg as methylprednisolone acetate, depending on joint size.

Dosage form	OINTMENT
Renal impairment	No dose adjustment required for renal impairment; methylprednisolone is primarily hepatically metabolized. However, monitor for fluid retention in severe renal impairment.
Liver impairment	Child-Pugh Class A: No adjustment. Child-Pugh Class B: Consider 50% dose reduction. Child-Pugh Class C: Use with caution; consider 50-75% dose reduction and monitor for adrenal suppression.
Pediatric use	Oral: 0.5-1.7 mg/kg/day or 5-25 mg/m²/day in divided doses every 6-12 hours. Intravenous: 0.5-1.7 mg/kg/day or 5-25 mg/m²/day as methylprednisolone sodium succinate. Intra-articular: 2-20 mg depending on joint size.
Geriatric use	Start at low end of dosing range due to increased risk of osteoporosis, glucose intolerance, and fluid retention. Titrate slowly and monitor for adverse effects. Adjust dose based on response and tolerance.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for NEO-MEDROL (NEO-MEDROL).

Breastfeeding	Minimal excretion into breast milk; M/P ratio unknown; doses <20 mg/day prednisone equivalent considered compatible with breastfeeding. Monitor infant for growth and adrenal suppression.
Teratogenic Risk	First trimester: Increased risk of cleft palate (odds ratio 3.35) and congenital heart defects. Second and third trimesters: Fetal growth restriction, adrenal suppression, and premature birth. Chronic use: Risk of neonatal adrenal insufficiency.
Fetal Monitoring

Warnings & precautions

■ FDA Black Box Warning

Topical corticosteroids should not be used in the treatment of diaper dermatitis. Prolonged use may lead to hypothalamic-pituitary-adrenal (HPA) axis suppression. Neomycin may cause ototoxicity when applied to open wounds or damaged skin.

Side Effect Profile

Serious Effects

Absolute Contraindications

Hypersensitivity to neomycin, methylprednisolone, or any component of the formulation; systemic fungal infections; ophthalmic use; use on infected skin lesions (unless accompanied by appropriate antimicrobial therapy).

Clinical Precautions

Precautions

Avoid prolonged use on large body surface areas or under occlusive dressings. Monitor for systemic corticosteroid effects, especially in children. Neomycin may cause allergic contact sensitization. Discontinue if irritation or infection develops.

Clinical Tips & Counseling

Drug interactions

Loading safety data…

NEO-MEDROL

Clinical safety rating: caution

Comprehensive clinical and safety monograph for NEO-MEDROL (NEO-MEDROL).

How it works

What the body does with it

Metabolism	Methylprednisolone is primarily metabolized in the liver via CYP3A4. Neomycin is minimally absorbed through intact skin; systemic absorption is negligible.
Excretion	Renal (primarily as inactive metabolites); <5% unchanged. Biliary/fecal excretion minimal.
Half-life	Plasma terminal half-life: 2-4 hours (methylprednisolone); clinical effect half-life ~18-36 hours due to receptor occupancy.
Protein binding	~78% bound to corticosteroid-binding globulin (CBG) and albumin.
Volume of Distribution	Approximately 0.8-1.2 L/kg, indicating extensive tissue distribution.
Bioavailability	Oral: 70-90%; IM: 100% (systemic); Intra-articular or soft-tissue injection: predominantly local with partial systemic absorption (variable).
Onset of Action	IV: rapid, within 30 minutes; IM: 1-2 hours; Oral: 2-4 hours.
Duration of Action	Single dose: 12-36 hours depending on dose and route; prolonged suppression of HPA axis can persist for weeks with chronic use.

Classification & Brands

Dosing & administration

Dosage form	OINTMENT
Renal impairment	No dose adjustment required for renal impairment; methylprednisolone is primarily hepatically metabolized. However, monitor for fluid retention in severe renal impairment.
Liver impairment	Child-Pugh Class A: No adjustment. Child-Pugh Class B: Consider 50% dose reduction. Child-Pugh Class C: Use with caution; consider 50-75% dose reduction and monitor for adrenal suppression.
Pediatric use	Oral: 0.5-1.7 mg/kg/day or 5-25 mg/m²/day in divided doses every 6-12 hours. Intravenous: 0.5-1.7 mg/kg/day or 5-25 mg/m²/day as methylprednisolone sodium succinate. Intra-articular: 2-20 mg depending on joint size.
Geriatric use	Start at low end of dosing range due to increased risk of osteoporosis, glucose intolerance, and fluid retention. Titrate slowly and monitor for adverse effects. Adjust dose based on response and tolerance.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for NEO-MEDROL (NEO-MEDROL).

Breastfeeding	Minimal excretion into breast milk; M/P ratio unknown; doses <20 mg/day prednisone equivalent considered compatible with breastfeeding. Monitor infant for growth and adrenal suppression.
Teratogenic Risk	First trimester: Increased risk of cleft palate (odds ratio 3.35) and congenital heart defects. Second and third trimesters: Fetal growth restriction, adrenal suppression, and premature birth. Chronic use: Risk of neonatal adrenal insufficiency.
Fetal Monitoring